Antidepressants: Past, Present and Future PDF Download

Author: Renato D. Alarcón
Publisher: Springer Science & Business Media
ISBN: 9783540430544
Category : Medical
Languages : en
Pages : 644

View

Book Description
With contribution by numerous experts

Author: Stephen M. Stahl
Publisher: Cambridge University Press
ISBN: 1139833014
Category : Medical
Languages : en
Pages : 199

View

Book Description
All of the titles in the Stahl's Illustrated Series are designed to be fun. Concepts are illustrated by full-color images that will be familiar to all readers of Stahl's Essential Psychopharmacology, 3rd Edition and The Prescriber's Guide. The texts in this user-friendly series can be supplements to figures, images, and tables. The visual learner will find that these books make psychopharmacology concepts easy to master, while the non-visual learner will enjoy a shortened text version of complex psychopharmacology concepts. Within each book, each chapter builds on previous chapters, synthesizing information from basic biology and diagnostics to building treatment plans and dealing with complications and comorbidities. Novices may want to approach Stahl's Illustrated Series by first looking through all the graphics and gaining a feel for the visual vocabulary. Readers more familiar with these topics should find that going back and forth between images and text provides an interaction with which to vividly conceptualize complex pharmacologies. And, to help guide the reader toward more in-depth learning about particular concepts, each book ends with a Suggested Reading section.

Author: Donald Mattison
Publisher: Academic Press
ISBN: 0123860075
Category : Medical
Languages : en
Pages : 496

View

Book Description
Clinical Pharmacology During Pregnancy is written for clinicians, physicians, midwives, nurses, pharmacists and other medical professionals directly involved in the care of women during pregnancy. This book focuses on the impact of pregnancy on drug disposition and also includes coverage of treatments for diseases of specific body systems, as well as essential content on dosing and efficacy. Written in a clear and practical manner, this reference provides easily accessible information and clinical guidance on how best to treat women with medications during pregnancy.

Author: S. Clare Stanford
Publisher: Landes Bioscience
ISBN:
Category : Medical
Languages : en
Pages : 248

View

Book Description
Details advantages and disadvantages of SSRIs. Starts with a personal memoir of the discovery of the first SSRI, then looks at SSRIs from the clinical point of view. Later chapters concentrate on preclinical material. A final chapter makes pharmacological and clinical comparisons between the tricycl

Author: Matthew Macaluso
Publisher: Springer
ISBN: 3030109496
Category : Medical
Languages : en
Pages : 442

View

Book Description
This volume reviews the known neurobiology of depression and combines classic data on antidepressant treatments with modern theory on the physiology of depression. It also discusses novel mechanism of action drugs.

Author: Alexander Glassman
Publisher: John Wiley & Sons
ISBN: 1119957621
Category : Medical
Languages : en
Pages : 110

View

Book Description
Recently, there has been a growing awareness of the multiple interrelationships between depression and various physical diseases. Patients with psychiatric problems, particularly depression, may be more susceptible to cardiovascular disorders. Depression and Heart Disease synthesizes current evidence, including some previously unpublished data, in a concise, easy-to-read format. The authors succinctly describe the epidemiology, pathogenesis (including cytokines and genetics), and risk factors of the comorbidity between depression and heart disease. The book also reviews the best pharmacological and psychotherapeutic approaches for people with this comorbidity.

Author:
Publisher: Academic Press
ISBN: 0128173173
Category : Medical
Languages : en
Pages : 290

View

Book Description
Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series

Author: Devidas Menon
Publisher:
ISBN:
Category : Antidepressants
Languages : en
Pages : 48

View

Book Description
Recent years have witnessed large increase in expenditures on antidepressants. This has coincided with the introduction and the widespread use of a new class of antidepressants, the selective serotonin reuptake inhibitors (SSRIs). SSRIs are substantially more expensive than the older tricyclic antidepressants (TCAs), but have a different adverse effect profile and are better tolerated. This study examines the cost-effectiveness of this new class of antidepressants as compared to TCAs in the outpatient treatment of depression. A decision model is built in order to compare three different strategies. The first strategy consists of an SSRI followed by a TCA in case of failure, the second strategy consists of a TCA followed by an SSRI in case of failure, and the third strategy consists of TCA only. The model indicates that the success rate of a short term treatment with an SSRI is higher than one with a TCA, but is also more expensive. However, as maintenance therapy is initiated, and the switch of medications is allowed for those who drop out of treatment, the cumulative success rate of SSRI first strategy becomes very similar to that of the TCA first strategy, but the cost of the SSRI first strategy increases over time. In comparison, when estimates of drop-out rates taken from studies conducted in naturalistic environments are substituted for clinical trial rates, this additional cost becomes increasingly small. If quality of life is considered, the SSRI first strategy offers improved quality of life over the TCA first strategy. In other words, an SSRI first-line strategy is dominant over a TCA only strategy, and an SSRI first-line strategy compared to a SSRI second-line strategy produces QALYs at an acceptable cost by current standards.

Author: Graziano Pinna
Publisher:
ISBN: 9781634820769
Category :
Languages : en
Pages : 412

View

Book Description
Fluoxetine, best known by the trade name Prozac®, unlike other psychotropic drugs whose effects were serendipitously stumbled upon, was the first developed for a precise mechanism of action, that is, the ability to selectively inhibit serotonin reuptake, based upon the theory that increasing the availability of serotonin would treat major depression. Once approved by the FDA in 1987, fluoxetine quickly became the most prescribed psychotropic drug worldwide and its success in improving mood disorders has triggered the development of a large number of congener molecules, commonly known as SSRIs after their purported mechanism of action. However, a quarter of a century after its development, the idea that fluoxetine asserts its positive behavioral effect through inhibition of serotonergic reuptake is not firmly established. This book reviews several preclinical and clinical reports suggesting that the pharmacological effects of fluoxetine may be mediated by means other than the regulation of serotonin, including the regulation of gene expression, modifying epigenetic mechanisms as well as modifying microRNAs. One of the most prominent mechanisms for the therapeutic relevance of fluoxetine relates to influencing neuroplasticity by enhancing neurotropic factors, including BDNF signaling and altering adult neurogenesis. The ability of fluoxetine to rapidly increase neurosteroid levels accounts for the fast anxiolytic effects of this drug. Fluoxetine action at sigma-1 receptor or modulating glutamatergic neurotransmission as well as the combination of fluoxetine with other psychotropic drugs is discussed in relation to its therapeutic effects. While fluoxetine was primarily prescribed as an antidepressant, this drug currently represents a treatment of choice for a broad spectrum of psychiatric disorders, including post-traumatic stress disorder and a range of anxiety disorders. This drug even possesses analgesic actions and is a valuable therapy for stroke. This book also highlights emerging evidence on the gender-specific effects of fluoxetine, its potential adverse features, including its addiction liability in combination with psychostimulants, and the impact of perinatal fluoxetine exposure.

Author: Peter D. Kramer
Publisher: Penguin
ISBN: 0140266712
Category : Psychology
Languages : en
Pages : 481

View

Book Description
The New York Times bestselling examination of the revolutionary antidepressant, with a new introduction and afterword reflecting on Prozac’s legacy and the latest medical research “Peter Kramer is an analyst of exceptional sensitivity and insight. To read his prose on virtually any subject is to be provoked, enthralled, illuminated.” —Joyce Carol Oates When antidepressants like Prozac first became available, Peter D. Kramer prescribed them, only to hear patients say that on medication, they felt different—less ill at ease, more like the person they had always imagined themselves to be. Referencing disciplines from cellular biology to animal ethology, Dr. Kramer worked to explain these reports. The result was Listening to Prozac, a revolutionary book that offered new perspectives on antidepressants, mood disorders, and our understanding of the self—and that became an instant national and international bestseller. In this thirtieth anniversary edition, Dr. Kramer looks back at the influence of his groundbreaking book, traces progress in the relevant sciences, follows trends in the use and public understanding of antidepressants, and assesses potential breakthroughs in the treatment of depression. The new introduction and afterword reinforce and reinvigorate a book that the New York Times called “originally insightful” and “intelligent and informative,” a window on a medicine that is “telling us new things about the chemistry of human character.”